Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
New England Journal of Medicine · 09.01.2025 · 392 (2) · 127-137
DOI: 10.1056/nejmoa2409368 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 09.01.2025. Verfasst von Gerald F Watts und 12 weiteren Autor:innen. Beteiligte Einrichtung: From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital - both in Perth, Australia (G.F.…. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hyperlipoproteinemia Type I, Pancreatitis, RNA, Small Interfering. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Persistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. METHODS: In a phase 3 trial, we randomly assigned 75 patients with persistent chylomicronemia (with or without a genetic diagnosis) to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months. The primary end point was the median percent change from baseline in the fasting triglyceride level at 10 months. Key secondary end points were the percent change in the fasting triglyceride level from baseline to the mean of values at 10 months and 12 months, changes in the fasting apolipoprotein C-III level from baseline to 10 months and 12 months, and the incidence of acute pancreatitis. RESULTS: At baseline, the median triglyceride level was 2044 mg per deciliter. At 10 months, the median change from baseline in the fasting triglyceride level (the primary end point) was -80% in the 25-mg plozasiran group, -78% in the 50-mg plozasiran group, and -17% in the placebo group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the School of Medicine, University of Western Australia, and the Department of Cardiology, Royal Perth Hospital - both in Perth, Australia (G.F.W.); the Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospi…
Förderung
- Arrowhead Pharmaceuticals
Zitieren
APA
Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., Leeper, N. J., Gaudet, D., & PALISADE Study Group (2025). Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. New England Journal of Medicine, 392(2), 127-137. https://doi.org/10.1056/nejmoa2409368
Vancouver
Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. New England Journal of Medicine. 2025;392(2):127-137. doi:10.1056/nejmoa2409368
BibTeX
@article{Watts2025,
author = {Watts, Gerald F and Rosenson, Robert S and Hegele, Robert A and Goldberg, Ira J and Gallo, Antonio and Mertens, Ann and Baass, Alexis and Zhou, Rong and Muhsin, Ma'an and Hellawell, Jennifer and Leeper, Nicholas J and Gaudet, Daniel and PALISADE Study Group, PALISADE Study Group},
title = {Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {2},
pages = {127--137},
doi = {10.1056/nejmoa2409368}
}
EUVIMED